AbbVie CEO Richard Gonzalez has set out his expectations for Humira in 2023, with the US market on the cusp of biosimilar competition from multiple adalimumab rivals.
As AbbVie prepares to face US biosimilar competition to Humira (adalimumab) within just a couple of weeks, the company’s CEO Richard Gonzalez has been setting out the company’s expectations for biosimilar competition to the top-selling immunology brand.
Despite so many biosimilars being set to launch in 2023 – including Amgen’s Amjevita (adalimumab-atto) coming as soon as the end of January (see sidebar) – Gonzalez insisted
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
